These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1433204)

  • 1. Design and synthesis of a C7 mimetic for the predicted gamma-turn conformation found in several constrained RGD antagonists.
    Callahan JF; Bean JW; Burgess JL; Eggleston DS; Hwang SM; Kopple KD; Koster PF; Nichols A; Peishoff CE; Samanen JM
    J Med Chem; 1992 Oct; 35(21):3970-2. PubMed ID: 1433204
    [No Abstract]   [Full Text] [Related]  

  • 2. Investigation of conformational specificity at GPIIb/IIIa: evaluation of conformationally constrained RGD peptides.
    Peishoff CE; Ali FE; Bean JW; Calvo R; D'Ambrosio CA; Eggleston DS; Hwang SM; Kline TP; Koster PF; Nichols A
    J Med Chem; 1992 Oct; 35(21):3962-9. PubMed ID: 1433203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro.
    Samanen J; Ali F; Romoff T; Calvo R; Sorenson E; Vasko J; Storer B; Berry D; Bennett D; Strohsacker M
    J Med Chem; 1991 Oct; 34(10):3114-25. PubMed ID: 1920361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of sulfur-free cyclic hexapeptides which contain the RGD sequence and bind to the fibrinogen GP IIb/IIIa receptor. A conformation-based correlation between propensity for imide formation and receptor affinity.
    Lender A; Yao W; Sprengeler PA; Spanevello RA; Furst GT; Hirschmann R; Smith AB
    Int J Pept Protein Res; 1993 Dec; 42(6):509-17. PubMed ID: 8307682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore refinement of gpIIb/IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides.
    Müller G; Gurrath M; Kessler H
    J Comput Aided Mol Des; 1994 Dec; 8(6):709-30. PubMed ID: 7738606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies.
    Pearson DA; Lister-James ; McBride WJ; Wilson DM; Martel LJ; Civitello ER; Dean RT
    J Med Chem; 1996 Mar; 39(7):1372-82. PubMed ID: 8691467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A three-residue cyclic scaffold of non-RGD containing peptide analogues as platelet aggregation inhibitors: design, synthesis, and structure--function relationships.
    Stavrakoudis A; Bizos G; Eleftheriadis D; Kouki A; Panou-Pomonis E; Sakarellos-Daitsiotis M; Sakarellos C; Tsoukatos D; Tsikaris V
    Biopolymers; 2000-2001; 56(1):20-6. PubMed ID: 11582574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library.
    O'Neil KT; Hoess RH; Jackson SA; Ramachandran NS; Mousa SA; DeGrado WF
    Proteins; 1992 Dec; 14(4):509-15. PubMed ID: 1438188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and evaluation of nonpeptide fibrinogen gamma-chain based GPIIb/IIIa antagonists.
    Hoekstra WJ; Beavers MP; Andrade-Gordon P; Evangelisto MF; Keane PM; Press JB; Tomko KA; Fan F; Kloczewiak M; Mayo KH
    J Med Chem; 1995 May; 38(10):1582-92. PubMed ID: 7752183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp.
    Varon D; Lider O; Dardik R; Shenkman B; Alon R; Hershkoviz R; Kapustina G; Savion N; Martinowitz U; Greenspoon N
    Thromb Haemost; 1993 Dec; 70(6):1030-6. PubMed ID: 8165596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic RGD peptide analogues as antiplatelet antithrombotics.
    Barker PL; Bullens S; Bunting S; Burdick DJ; Chan KS; Deisher T; Eigenbrot C; Gadek TR; Gantzos R; Lipari MT
    J Med Chem; 1992 May; 35(11):2040-8. PubMed ID: 1597855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.
    Hartman GD; Egbertson MS; Halczenko W; Laswell WL; Duggan ME; Smith RL; Naylor AM; Manno PD; Lynch RJ; Zhang G
    J Med Chem; 1992 Nov; 35(24):4640-2. PubMed ID: 1469694
    [No Abstract]   [Full Text] [Related]  

  • 13. Solution structure of a cyclic RGD peptide that inhibits platelet aggregation.
    Jois SD; Tambunan US; Chakrabarti S; Siahaan TJ
    J Biomol Struct Dyn; 1996 Aug; 14(1):1-11. PubMed ID: 8877556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides.
    Gurrath M; Müller G; Kessler H; Aumailley M; Timpl R
    Eur J Biochem; 1992 Dec; 210(3):911-21. PubMed ID: 1483474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of [3H]-SK&F 107260 and [3H]-SB 214857 to purified integrin alphaIIbbeta3: evidence for a common binding site for cyclic arginyl-glycinyl-aspartic acid peptides and nonpeptides.
    Wong A; Hwang SM; Johanson K; Samanen J; Bennett D; Landvatter SW; Chen W; Heys JR; Ali FE; Ku TW; Bondinell W; Nichols AJ; Powers DA; Stadel JM
    J Pharmacol Exp Ther; 1998 Apr; 285(1):228-35. PubMed ID: 9536015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists.
    Zablocki JA; Rico JG; Garland RB; Rogers TE; Williams K; Schretzman LA; Rao SA; Bovy PR; Tjoeng FS; Lindmark RJ
    J Med Chem; 1995 Jun; 38(13):2378-94. PubMed ID: 7608903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation.
    Ali FE; Bennett DB; Calvo RR; Elliott JD; Hwang SM; Ku TW; Lago MA; Nichols AJ; Romoff TT; Shah DH
    J Med Chem; 1994 Mar; 37(6):769-80. PubMed ID: 8145226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent non-peptide fibrinogen receptor antagonists which present an alternative pharmacophore.
    Ku TW; Miller WH; Bondinell WE; Erhard KF; Keenan RM; Nichols AJ; Peishoff CE; Samanen JM; Wong AS; Huffman WF
    J Med Chem; 1995 Jan; 38(1):9-12. PubMed ID: 7837245
    [No Abstract]   [Full Text] [Related]  

  • 19. A synthetic peptide with anti-platelet activity derived from a CDR of an anti-GPIIb-IIIa antibody.
    Jarrin A; Andrieux A; Chapel A; Buchou T; Marguerie G
    FEBS Lett; 1994 Nov; 354(2):169-72. PubMed ID: 7957919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta 3 integrin derived peptide 217-230 inhibits fibrinogen binding and platelet aggregation: significance of RGD sequences and fibrinogen A alpha-chain.
    Lasz EC; McLane MA; Trybulec M; Kowalska MA; Khan S; Budzynski AZ; Niewiarowski S
    Biochem Biophys Res Commun; 1993 Jan; 190(1):118-24. PubMed ID: 8422238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.